JG
RLAY icon

Joel Greenblatt’s Relay Therapeutics RLAY Stock Holding History

Joel Greenblatt’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33,606
Closed -$334K – 1870
2026
Q1 		$334K Buy
+33,606
New +$301K ﹤0.01% 1583
2024
Q1 		– Sell
-16,135
Closed -$178K – 1444
2023
Q4 		$178K Buy
+16,135
New +$136K ﹤0.01% 1265
2021
Q4 		– Sell
-7,394
Closed -$233K – 1224
2021
Q3 		$233K Sell
7,394
-4,028
-35% -$136K 0.01% 924
2021
Q2 		$418K Buy
+11,422
New +$376K 0.02% 742

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Joel Greenblatt's RLAY Position: Q2 2026 in Review

Joel Greenblatt sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 33,606 shares — an estimated $334K sold.

Joel Greenblatt first reported a position in RLAY in Q2 2021 and held it in 4 quarters. The position peaked at $418K in Q2 2021. 256 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Joel Greenblatt reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Joel Greenblatt sold 33,606 Relay Therapeutics shares in Q2 2026, an estimated $334K.
  • Joel Greenblatt first reported a position in Relay Therapeutics in Q2 2021 and held it in 4 quarters.
  • Joel Greenblatt's Relay Therapeutics position peaked at $418K in Q2 2021.
  • 256 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.